generation run 2026-05-11
72 min completedmodel pipeline-v5plan not recordedrun/72ddbd09…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- sparse_evidence
- structural_inference_avoided
Reproduce
- inputs
- 24 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
16 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | OpenAlex | fenethylline captagon pharmacology | 10 | 4 | High-citation comprehensive reviews and landmark papers on fenethylline |
| 2 | PubMed | captagon Syria production trafficking economy geopolitics | 1 | 1 | Comprehensive regional context review |
| 3 | PubMed | Captagon amphetamine theophylline | 10 | 8 | All directly relevant to fenethylline/captagon toxicity, cardiovascular effects, psychiatric effects, and abuse patterns |
| 4 | PubChem | fenethylline | 1 | 1 | Chemical identity verification — confirms key structural data for the brief |
| 5 | PubMed | fenethylline pharmacology pharmacokinetics | 4 | 4 | All directly relevant to pharmacokinetics and metabolism of fenethylline |
| 6 | PubMed | get article 27004621 | 1 | 1 | Most comprehensive review available — covers chemistry, synthesis, pharmacology, toxicology, legislation, prevalence |
| 7 | PubMed | fenethylline metabolism amphetamine theophylline prodrug | 3 | 2 | Prodrug hypothesis and EEG characterization of fenethylline |
| 8 | ClinicalTrials.gov · absence | fenethylline captagon | 0 | — | Confirms absence of any current clinical trial activity |
| 9 | PubMed | get articles 38550445, 39512334, 36913784, 40397316 | 4 | 4 | Narrative review, bibliometric, cardiovascular adverse effects, and BDNF neurotoxicity data |
| 10 | WebSearch | fenethylline captagon WADA banned list sports doping physical properties melting point | 10 | 2 | Physical property and doping context data |
| 11 | legislation.gov.uk | fenethylline UK Misuse of Drugs Act 1986 | 1 | 1 | Official UK legal source |
| 12 | WebSearch | fenethylline captagon history 1961 synthesis Degussa Germany first clinical use ADHD narcolepsy | 10 | 2 | History and synthesis data not available in PubMed abstracts |
| 13 | WikiDoc | fenethylline legal status pharmacokinetics | 1 | 3 | Concise legal/PK data not consolidated elsewhere |
| 14 | PubMed | captagon Jordan university students prevalence reasons use | 1 | 1 | Prevalence and motivations for captagon use in student populations |
| 15 | WebSearch | fenethylline DEA Schedule I 1981 Convention Psychotropic Substances 1986 UK Class A legal status | 10 | 2 | Legal status verification for key jurisdictions |
| 16 | WebSearch | captagon tramadol interaction fatal death serotonin syndrome case report | 10 | 0 | Investigating the 'lethal' interaction severity listed in the brief - found no primary source to verify this |
82 claims by section — every cited sentence, checked against its source
safety27 · 18 ok
The amphetamine metabolite inhibits CYP2D6supported
CYP2D6 competition by amphetamine retards theophylline metabolism. s41598-018-35449-6
Claim in safety — inconclusiveinconclusiveworking →
Acute myocardial infarction: Gokdemir and Giden reported a case of acute inferior myocardial infarction in a 23-year-old male following captagon ingestion, attributed to coronary vasospasm and thrombus destabilization.supported
23-year-old developed acute myocardial infarction after captagon tablet use. Attributed to vessel wall narrowing and thrombus destabilization. j.tjem.2018.05.001
Brugada phenocopy: Gul and colleagues documented two cases of reversible type 1B Brugada ECG pattern associated with fenethylline abuse, both resolving after discontinuationsupported
Two cases of type 1B Brugada phenocopy associated with Fenethylline abuse. j.jelectrocard.2023.03.002
QT prolongation: Rat models of captagon exposure demonstrate elevated ST segments and prolonged QT intervals, with cardiac biomarker elevation (LDH, cardiac troponin I).supported
Elevated LDH, cTnI, ECG changes including prolonged QT interval. j.toxlet.2025.04.002
Claim in safety — inconclusiveinconclusiveworking →
Shehata and colleagues demonstrated synergistic cardiotoxicity when captagon is combined with azithromycin in a rat modelsupported
Co-usage of Captagon and azithromycin causes synergistic cardiotoxicity in rats via oxidative stress, inflammation, and apoptosis. j.toxlet.2025.04.002
Counterfeit captagon formulations produce significantly greater hyperthermia and locomotor effects than genuine fenethylline at comparable doses, and — unlike genuine fenethylline — reduce BDNF mRNA in the prefrontal cortexsupported
CC significantly increased body temperature and locomotor activity vs FEN, higher hyperthermia risk. CC caused significant BDNF mRNA reduction in prefrontal cortex. s44446-025-00007-5
In a series of 101 male inpatients in Saudi Arabia with captagon-induced psychosis, regular daily doses ranged from 1–15 tablets and maximum daily doses from 2–25 tabletssupported
101 male patients with captagon-induced psychosis. Daily dose 1-15 tablets, maximum 2-25 tablets. pmid:36873918
A distinctive feature was the prevalence of delusions of infidelity (morbid jealousy) in 25.7% of cases, associated with a 53.8% divorce rate in that subgroup.partially supported
25.7% developed infidelity delusions... Higher divorce rate among infidelity delusion patients. pmid:36873918
Hallucinations and visual distortions — documented as the reason for fenethylline's withdrawal from the US market — represent dose-dependent psychiatric toxicity that emerges at supratherapeutic dosessupported
Withdrawn from US market for hallucinations, visual distortions, psychosis. cureus.55053
Claim in safety — inconclusiveinconclusiveworking →
Combat and conflict use — characterized by high doses sustained over days — represents an extreme exposure pattern associated with maximal psychiatric risk.supported
Combat use described: euphoric, fearless, awake for days. add.13262
Fenethylline's classification under Schedule I (US) and international prohibition under the Convention on Psychotropic Substances were driven in part by documented addictive potentialsupported
Classified Schedule 1 due to addictive/hallucinogenic properties. Global prohibition 1986. j.jsps.2024.102188
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Qualitative reports from captagon users in Jordan describe withdrawal symptoms consistent with amphetamine-class withdrawal: crash and fatigue, depression, craving, and sleep disturbancesupported
Themes: sought effects, downsides/withdrawal, motivations, COVID-19 impact. 10826084.2024.2304012
Claim in safety — inconclusiveinconclusiveworking →
The dual pharmacology introduces theoretical complexity: while amphetamine-type tolerance (dopaminergic receptor downregulation) would be expected, the CYP2D6 inhibition by the amphetamine metabolite retards theophylline clearance, potentially attenuating metabolic tolerance to the adenosinergic componentsupported
CYP2D6 competition by amphetamine retards theophylline metabolism. s41598-018-35449-6
The captagon + azithromycin combination specifically has been shown to produce synergistic QT prolongation, oxidative stress, and cardiac apoptosis in rat models.supported
Co-usage of Captagon and azithromycin causes synergistic cardiotoxicity in rats via oxidative stress, inflammation, and apoptosis. ECG changes including prolonged QT interval. j.toxlet.2025.04.002
Claim in safety — inconclusiveinconclusiveworking →
Recent myocardial infarction or unstable angina: Amphetamine-class coronary vasospasm risk, documented in case report.supported
23-year-old developed acute myocardial infarction after captagon tablet use. Attributed to vessel wall narrowing and thrombus destabilization. j.tjem.2018.05.001
Cardiac conduction abnormalities or prolonged QT: Risk of arrhythmia, particularly in combination with QT-prolonging medications.supported
Co-usage of Captagon and azithromycin causes synergistic cardiotoxicity in rats. ECG changes including prolonged QT interval. j.toxlet.2025.04.002
History of psychotic disorders or first-degree family history of schizophrenia: Dose-dependent psychosis risk, documented at 25.7% incidence of morbid jealousy delusions in a clinical captagon psychosis population.supported
101 male patients with captagon-induced psychosis. 25.7% developed infidelity delusions. pmid:36873918
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Concurrent use of CYP2D6-metabolized drugs with narrow therapeutic indices: Risk of elevated plasma levels of co-administered drugs.supported
CYP2D6 competition by amphetamine retards theophylline metabolism. s41598-018-35449-6
pharmacology14 · 12 ok
While oxidative cleavage releases amphetamine and theophylline, the intact parent molecule exerts intrinsic pharmacological activity — pharmacodynamic effects track more closely with parent-compound plasma levels than with metabolite concentrations.supported
Fenetylline has own activity — only small amounts of amphetamine released. Pharmacodynamic activity tied to parent compound plasma levels rather than metabolites. pmid:3743407
It also functions as an agonist at trace amine-associated receptor 1 (TAAR1), a mechanism identified as the primary driver of captagon's addictive potential and its propensity to produce irritability and aggressionpartially supported
Amphetamine is TAAR1 agonist; theophylline blocks A2aR. s41598-018-35449-6
A₂A receptor blockade in the striatum attenuates behavioral sensitization caused by the amphetamine component, a finding that may explain why fenethylline produces lower abuse potential than pure amphetaminepartially supported
theophylline blocks A2aR. Synergies cause faster, more potent psychoactive effects than amphetamine alone. s41598-018-35449-6
Wu and colleagues demonstrated via systems pharmacology and molecular docking that concurrent TAAR1 agonism (amphetamine) and A₂A antagonism (theophylline) produces faster and more potent psychoactive effects than either metabolite alonesupported
Synergies cause faster, more potent psychoactive effects than amphetamine alone. s41598-018-35449-6
A further metabolic synergy exists: the amphetamine metabolite competitively inhibits CYP2D6, which participates in theophylline clearance, thereby retarding theophylline elimination and extending its duration of action.supported
CYP2D6 competition by amphetamine retards theophylline metabolism. s41598-018-35449-6
At recreational and abuse doses, this protective offset is overwhelmed: vasoconstrictive and pro-arrhythmic effects dominate, as documented by case reports of Brugada phenocopy and acute myocardial infarction.supported
Two cases of type 1B Brugada phenocopy associated with Fenethylline abuse. j.jelectrocard.2023.03.002
At recreational and abuse doses, this protective offset is overwhelmed: vasoconstrictive and pro-arrhythmic effects dominate, as documented by case reports of Brugada phenocopy and acute myocardial infarction.supported
23-year-old developed acute myocardial infarction after captagon tablet use. Attributed to vessel wall narrowing and thrombus destabilization. j.tjem.2018.05.001
Yoshimura and colleagues administered fenethylline to three male human volunteers and characterized urinary metabolites over 48 hourssupported
Metabolic fate in rats and 3 male volunteers. Six metabolites identified. pmid:3188572
Rücker and colleagues subsequently identified seven additional metabolites by GC/MS, expanding the metabolic profile beyond the four originally characterizedsupported
After oral administration, 7 new metabolites detected in urine besides 4 known substances. Identified by GC and GC/MS. pmid:3401264
Notably, only small fractions of the amphetamine theoretically available in the fenethylline molecule are actually released, consistent with the observation that the parent compound — not its metabolites — drives the acute pharmacodynamic profile.supported
only small amounts of amphetamine released. Pharmacodynamic activity tied to parent compound plasma levels rather than metabolites. pmid:3743407
Claim in pharmacology — inconclusiveinconclusiveworking →
The amphetamine metabolite's competitive inhibition of CYP2D6 creates a pharmacokinetic feedback loop: as amphetamine accumulates, theophylline clearance slows, amplifying the duration of the theophylline contribution.supported
CYP2D6 competition by amphetamine retards theophylline metabolism. s41598-018-35449-6
Claim in pharmacology — inconclusiveinconclusiveworking →
Fenethylline is listed among precursor medications capable of producing amphetamine-positive drug test results.supported
Reviews precursor drugs metabolized to amphetamine/methamphetamine including fenethylline. Clinical indications and drug testing implications. pmid:12024689
history11 · 6 ok
In 1986, the World Health Organization added fenethylline to the Convention on Psychotropic Substances (1971), citing addictive and hallucinogenic properties, which triggered prohibition across most signatory nationssupported
international prohibition 1986 add.13262
Claim in history — inconclusiveinconclusiveworking →
It saw clinical use across Europe and briefly in the United States before being withdrawn from the American market due to adverse psychiatric effects — hallucinations, visual distortions, and psychosis — that emerged during post-marketing surveillancesupported
First developed in the 1960s in Europe and approved briefly in the US... Withdrawn from US market for hallucinations, visual distortions, psychosis. cureus.55053
That same year, Dimpfel and colleagues confirmed this via quantitative radioelectroencephalography in rats, showing an EEG fingerprint distinct from either amphetamine or theophylline alone.supported
Fenetylline has own intrinsic mode of action — not merely prodrug. EEG fingerprint resembles theophylline for alpha activity, amphetamine for beta1 activity. pmid:3531913
The United States placed fenethylline on Schedule I in 1981, designating it as having no accepted medical use and high abuse potentialsupported
controlled US Schedule I 1981 add.13262
Claim in history — inconclusiveinconclusiveworking →
In 2013, Syria displaced Lebanon as the premier producer and exporter of counterfeit captagon, with 12.3 million pills seized near the Lebanon–Syria border that yearpartially supported
Syria premier producer since 2013. add.13262
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Forensic analyses have identified contents including amphetamine, methamphetamine, caffeine, procaine, quinine, ephedrine, metronidazole, theophylline, chlorphenamine, trimethoprim, chloroquine, lidocaine, and diphenhydraminepartially supported
Counterfeit pill contents include amphetamine, procaine, caffeine, quinine, ephedrine. add.13262
summary8 · 7 ok
Synthesized in 1961 at Degussa AG in Germany, fenethylline was prescribed across Europe for hyperkinetic disorders, narcolepsy, and depression until international prohibition in 1986 under the Convention on Psychotropic Substancessupported
Introduced 1961 for hyperactivity, depression, narcolepsy. Classified Schedule 1 due to addictive/hallucinogenic properties. Global prohibition 1986. j.jsps.2024.102188
The compound's contemporary significance is overwhelmingly forensic and geopolitical: since the early 2000s, billions of tablets branded "Captagon" — most containing no genuine fenethylline — have fueled a narcotics economy across the Arabian Peninsula and conflict zones of the Levant.supported
Counterfeit pill contents include amphetamine, procaine, caffeine, quinine, ephedrine. Syria premier producer since 2013. add.13262
While metabolic cleavage releases amphetamine (23–33% of dose) and theophylline (approximately 13.7% of dose), pharmacodynamic effects correlate more closely with intact parent-compound plasma levels than with metabolite concentrationspartially supported
Fenetylline has own activity — only small amounts of amphetamine released. Pharmacodynamic activity tied to parent compound plasma levels rather than metabolites. pmid:3743407
The amphetamine component drives monoamine release via DAT/NET reverse transport and TAAR1 agonism, while the theophylline component antagonizes adenosine A₁ and A₂A receptors; A₂A blockade in the striatum attenuates amphetamine-induced behavioral sensitization, potentially reducing abuse liability relative to pure amphetaminepartially supported
Amphetamine is TAAR1 agonist; theophylline blocks A2aR. Synergies cause faster, more potent psychoactive effects than amphetamine alone. s41598-018-35449-6
Claim in summary — inconclusiveinconclusiveworking →
Cardiovascular toxicity — including acute myocardial infarction and Brugada phenocopy — is documented in case reports at abuse dosessupported
Two cases of type 1B Brugada phenocopy associated with Fenethylline abuse. j.jelectrocard.2023.03.002
Cardiovascular toxicity — including acute myocardial infarction and Brugada phenocopy — is documented in case reports at abuse dosessupported
23-year-old developed acute myocardial infarction after captagon tablet use. j.tjem.2018.05.001
Psychiatric toxicity, including stimulant psychosis with delusions of morbid jealousy, emerges at high chronic dosessupported
101 male patients with captagon-induced psychosis. 25.7% developed infidelity delusions. pmid:36873918
clinical-evidence5 · 3 ok
Wazaify and colleagues explored qualitative experiences of people who use captagon and therapists in Jordan, providing primary descriptions of withdrawal symptoms and addiction trajectories.supported
Qualitative study with 27 participants (20 users, 7 therapists) in Jordan. Themes: sought effects, downsides/withdrawal, motivations, COVID-19 impact. 10826084.2024.2304012
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Shalaby and colleagues studied 101 male inpatients in Saudi Arabia with captagon-induced psychosissupported
101 male patients with captagon-induced psychosis. pmid:36873918
Al Omari and colleagues published a qualitative study of Jordanian university students' lived experiences with captagon, documenting motivations including fatigue reduction, enhanced focus, and academic performance pressuresupported
Qualitative study of Jordanian university students misusing captagon. Explores motivations, effects experienced, and consequences. jan.0000000000000446
comparative-pharmacology4 · 4 ok
Metabolite yield: Only 23–33% of the fenethylline dose is recovered as amphetamine in urine, meaning that a 50 mg fenethylline tablet delivers roughly 12–17 mg of amphetamine equivalent — substantially less than a comparable amphetamine dosesupported
amphetamine (23-33% dose) were major urinary metabolites. pmid:3188572
Althobaiti and colleagues directly compared genuine fenethylline (50–100 mg/kg, rat) with counterfeit captagon formulationssupported
Compared genuine fenethylline vs counterfeit captagon in rats. s44446-025-00007-5
Abuse liability: Wu and colleagues proposed that A₂A receptor antagonism by the theophylline component attenuates amphetamine-induced behavioral sensitization in the striatum, which could translate to reduced abuse potential for fenethylline relative to amphetaminepartially supported
theophylline blocks A2aR. Synergies cause faster, more potent psychoactive effects than amphetamine alone. s41598-018-35449-6
Neurophysiological fingerprint: Quantitative radioelectroencephalography in rats demonstrates that fenethylline produces a combined pattern — reduced alpha activity (theophylline-like) and increased beta-1 activity (amphetamine-like) — that is not reproduced by either metabolite alonesupported
Fenetylline has own intrinsic mode of action — not merely prodrug. EEG fingerprint resembles theophylline for alpha activity, amphetamine for beta1 activity. pmid:3531913
neuroscience4 · 2 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
Claim in neuroscience — inconclusiveinconclusiveworking →
In animal models, A₂A receptor blockade attenuates this sensitization, raising the possibility that fenethylline's dual pharmacology partially protects against the sensitization trajectory that drives escalating amphetamine usepartially supported
theophylline blocks A2aR. Synergies cause faster, more potent psychoactive effects than amphetamine alone. s41598-018-35449-6
Conversely, CYP2D6 inhibition by the amphetamine metabolite slows theophylline clearance, potentially attenuating metabolic tolerance to the theophylline component and maintaining adenosinergic effects over repeated dosing.supported
CYP2D6 competition by amphetamine retards theophylline metabolism. s41598-018-35449-6
pharmacokinetic-detail3 · 2 ok
The sole published human metabolic study enrolled three male volunteers and tracked urinary excretion over 48 hourssupported
Metabolic fate in rats and 3 male volunteers. pmid:3188572
Rücker and colleagues extended this metabolic map by identifying seven additional metabolites via GC/MS beyond the four originally characterized, including hydroxylated and acetylated theophylline derivatives.supported
After oral administration, 7 new metabolites detected in urine besides 4 known substances. Identified by GC and GC/MS. pmid:3401264
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
receptor-pharmacology3 · 2 ok
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
Adenosine A₂A receptor: Antagonist. Striatal A₂A blockade attenuates amphetamine-induced behavioral sensitization, a mechanism proposed to explain why fenethylline may carry lower abuse potential than pure amphetamine.partially supported
theophylline blocks A2aR. Synergies cause faster, more potent psychoactive effects than amphetamine alone. s41598-018-35449-6
However, two lines of evidence demonstrate intrinsic activity: (1) pharmacodynamic effects correlate with parent-compound plasma levels rather than metabolite levels, and (2) the EEG fingerprint of fenethylline in freely moving rats combines features of both theophylline (reduced alpha activity) and amphetamine (increased beta-1 activity) in a pattern distinct from either metabolite administered alonesupported
Pharmacodynamic activity tied to parent compound plasma levels rather than metabolites. pmid:3743407
legal-status2 · 1 ok
International scheduling occurred in 1986, when the World Health Organization added fenethylline to the Convention, citing addictive and hallucinogenic propertiessupported
Classified Schedule 1 due to addictive/hallucinogenic properties. Global prohibition 1986. j.jsps.2024.102188
Claim in legal-status — inconclusiveinconclusiveworking →
chemistry1 · 1 ok
Its molecular architecture is a covalent conjugate in which a theophylline (1,3-dimethylxanthine) moiety is linked via a two-carbon ethylamine bridge to a d,l-amphetamine moietysupported
Theophylline covalently linked with amphetamine. pmid:3743407